Warburg Pincus led a $171m Series B round in HaiHe Biopharma, a biotechnology company focused on the discovery and development of innovative oncology drugs. The round saw participation from CMB International, Legend Capital, a fund under CICC Capital, Chaos Investment, Beijing Langzi Asiana Asset Management, Winfast Holding, SSIC Capital, as well as the company’s Series A round investors Biotrack Capital, Yingke PE, Atlas Venture Capital and CSPC. The funds raised will primarily be used to accelerate the global development and product launch of HaiHe Biopharma's multiple new oncology drugs.